<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 22, 1998
------------------------------
KING PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
-----------------------------
Not Applicable
- -------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since
last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
Effective as of December 22, 1998, King Pharmaceuticals, Inc.,
a Tennessee corporation, acquired three branded prescription pharmaceutical
products from Hoechst Marion Roussel. The products acquired include certain U.
S. rights to Altace(R) (ramipril), an Angiotensin Converting Enzyme ("ACE")
inhibitor, and certain worldwide rights to AVC(TM) (sulfanilamide), a vaginal
anti-infective cream, and to Silvadene(R) (silver sulfadiazine), a burn cream.
The purchase price of $362.5 million was financed by a group of financial
institutions including Credit Suisse First Boston, First Union National Bank and
Bank of America with a portion of the proceeds of a senior secured credit
facility of $500 million. In addition to the acquisition of the three branded
products, the proceeds of the credit facility were used to refinance certain
existing indebtedness, to fund working capital requirements and for general
corporate purposes.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements on Businesses Acquired.
The financial statements required to be filed pursuant to Item
7(a)(1) are not included with this report. In accordance with Item 7(a)(4), the
Registrant will file such statements by amendment to this Form 8-K no later than
March 8, 1999.
(b) Pro Forma Financial Information.
The pro forma financial information required to be filed
pursuant to Item 7(b) is not included with this report. In accordance with Item
7(b)(2), the Registrant will file such financial information by amendment to
this Form 8-K no later than March 8, 1999.
(c) Exhibits.
The following exhibits are filed pursuant to Item 601 of
Regulation S-K:
<TABLE>
<CAPTION>
Exhibit
Number Description
------ -----------
<S> <C>
2.1 General Products Agreement dated as of December 17, 1998, by and
among Hoechst Marion Roussel, Inc., Hoechst Marion Roussel,
Deutschland GmbH, and King Pharmaceuticals, Inc.
99 Press Releases of King Pharmaceuticals, Inc. dated December 17,
1998 and December 22, 1998
</TABLE>
- 1 -
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: January 5, 1999
By: /s/ Brian G. Shrader
------------------------------------
Brian G. Shrader
Chief Financial Officer
<PAGE> 1
Exhibit 2.1
GENERAL PRODUCTS AGREEMENT
THIS GENERAL PRODUCTS AGREEMENT (the "Agreement"), dated as of December 17,
1998, is made and entered into by and among HOECHST MARION ROUSSEL, INC., a
Delaware corporation ("HMRI"), HOECHST MARION ROUSSEL DEUTSCHLAND GMBH, a German
limited liability company ("HMR GmbH") (together, HMRI and HMR GmbH are
referred to herein as "Sellers"), and KING PHARMACEUTICALS, INC., a Tennessee
corporation ("Purchaser"). Capitalized terms used in this Agreement shall have
the meanings ascribed to them in Article I hereof or as otherwise set forth
herein.
RECITALS
WHEREAS, Sellers are engaged in the business of (i) manufacturing and
selling the pharmaceutical product ramipril, sold in the United States under the
registered trademark Altace(R) (the "U.S. Product"), and owns or licenses
certain rights related to Ramipril (as such term is defined in the U.S. Product
Agreement), and (ii) manufacturing and selling the pharmaceutical products sold
under the trademarks AVC, DV and Silvadene(R) (the "International Products");
WHEREAS, Sellers desire to sell, transfer and assign to Purchaser, and
Purchaser desires to purchase and acquire from Sellers, assets of Sellers
relating to the International Products and assets of Sellers relating to the
U.S. Product, and in connection therewith, Purchaser has agreed to assume
certain of the liabilities of Sellers relating to the International Products and
the U.S. Product, all on the terms set forth herein; and
WHEREAS, this Agreement is being entered into in connection with the
transactions pursuant to which at the time of Closing (i) Purchaser and Sellers
shall enter into that certain U.S. Product Agreement in the form of Exhibit 1
(the "U.S. Product Agreement"), (ii) Purchaser and Sellers shall enter into that
certain U.S. Product Manufacturing Agreement in the form of Exhibit 2 hereto
(the "U.S. Product Manufacturing Agreement"), (iii) Purchaser and HMRI shall
enter into that certain International Products Manufacturing Agreement in the
form of Exhibit 3 hereto (the "International Products Manufacturing Agreement"),
and (iv) Purchaser and HMRI shall enter into that certain Transition Services
Agreement in the form of Exhibit 4 hereto (the "Transition Services Agreement").
NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth in this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto
hereby agree as follows:
ARTICLE I
DEFINITIONS
The following terms shall have the meanings set forth below. Unless the
context indicates otherwise, the singular shall include the plural and the
plural shall include the singular.
<PAGE> 2
1.1 "AVC" shall mean all formulations of the finished product
sold by Sellers which has as its active ingredient sulfanilamide.
1.2 "AFFILIATE" shall mean any entity that directly, or
indirectly through one or more intermediaries, controls or is controlled by or
is under common control with the party specified.
1.3 "AGREEMENT" shall have the meaning set forth in the
preamble.
1.4 "ANNUAL AGGREGATE GROSS SALES" shall have the meaning set
forth in Section 2.3(b)(B) herein.
1.5 "ASSETS" shall mean the International Products Assets and
the U.S. Product Assets.
1.6 "ASSIGNMENT INSTRUMENTS" shall have the meaning set forth
in Section 2.4(b) herein.
1.7 "ASSIGNMENT OF TRADEMARKS" shall have the meaning set
forth in Section 2.4(b) herein.
1.8 "ASSUMED CONTRACTS" shall mean the International Assumed
Contracts and the U.S. Assumed Contracts.
1.9 "ASSUMED LIABILITIES" shall have the meaning set forth in
Section 2.2 herein.
1.10 "ASSUMPTION INSTRUMENTS" shall have the meaning set forth
in Section 2.4(b) herein.
1.11 "Business Day" or "business day" shall mean a day other
than Saturday, Sunday or any day on which banks located in the State of Missouri
are authorized or obligated to close. Whenever this Agreement refers to a number
of days, such number shall refer to calendar days unless Business Days (or
business days) are specified.
1.12 "CLOSING" shall mean the consummation of the transactions
contemplated herein.
1.13 "CLOSING DATE" shall mean (a) December 22, 1998, or (b)
such other date as Purchaser and Sellers mutually agree upon in writing.
1.14 "CONTINGENT CONSIDERATION" shall have the meaning set
forth in Section 2.3(b)(B) herein.
2
<PAGE> 3
1.15 "DV" shall mean all formulations of the finished product
previously sold by Sellers which has as its active ingredient dienestrol.
1.16 "FDA" shall mean the United States Food and Drug
Administration or any successor entity thereto.
1.17 "FORCE MAJEURE" shall have the meaning set forth in
Section 8.8 herein.
1.18 "GENERAL ASSIGNMENT AND ASSUMPTION" shall have the
meaning set forth in Section 2.4 herein.
1.19 "GOVERNMENTAL OR REGULATORY AUTHORITY" shall mean any
court, tribunal, arbitrator, authority, agency, commission, official or other
instrumentality of the United States, any foreign country or any domestic or
foreign state, county, city or other political subdivision.
1.20 "INDEMNITEE" shall have the meaning set forth in Section
6.2 herein.
1.21 "INDEMNITOR" shall have the meaning set forth in Section
6.2(a) herein.
1.22 "INTERNATIONAL ASSUMED CONTRACTS" shall have the meaning
set forth in Section 2.1(a)(vii) herein.
1.23 "INTERNATIONAL AUTHORIZATIONS" shall have the meaning set
forth in Section 2.1(a)(iii) herein.
1.24 "INTERNATIONAL PRODUCTS" shall have the meaning set forth
in the Recitals.
1.25 "INTERNATIONAL PRODUCTS ASSETS" shall have the meaning
set forth in Section 2.1(a) herein.
1.26 "INTERNATIONAL PRODUCTS MANUFACTURING AGREEMENT" shall
have the meaning set forth in the Recitals.
1.27 "INTERNATIONAL TERRITORY" shall mean all jurisdictions
throughout the world where the International Products are currently being sold,
or could be sold, by Sellers or any of their Affiliates.
1.28 "INTERNATIONAL TRADEMARKS" shall have the meaning set
forth in Section 2.1(a)(i) herein.
1.29 "KNOW-HOW" shall mean manufacturing information,
technical information, clinical information, regulatory information, know-how
and inventions, patentable and non-patentable,
3
<PAGE> 4
owned by Sellers and relating to the International Products to the extent
Sellers are not contractually or otherwise restricted or prohibited from
disclosing and/or granting rights to such know-how and excluding any items
described on SCHEDULE 1.29.
1.30 "Knowledge" OR "knowledge" shall mean actual knowledge
after reasonable investigation by any executive officer of those things which a
reasonably diligent inquiry and exercise of means of information at hand would
have disclosed.
1.31 "LAWS" shall mean all laws, statutes, rules, regulations,
ordinances and other pronouncements having the effect of law of the United
States, any foreign country or any domestic or foreign state, county, city or
other political subdivision or of any Governmental or Regulatory Authority.
1.32 "LETTERS OF CREDIT" shall have the meaning set forth in
Section 5.2(g) herein.
1.33 "LOSSES" shall mean any and all liabilities, debts,
obligations, damages, fines, penalties, deficiencies, losses and expenses
(including, without limitation, interest, court costs, amounts paid in
settlement, reasonable fees of attorneys, accountants and other experts or other
reasonable expenses of litigation or other proceedings or of any claim, default
or assessment).
1.34 "NOTE PURCHASE AGREEMENTS" shall have the meaning set
forth in Section 5.2(f) herein.
1.35 "OPERATIVE AGREEMENTS" shall mean, collectively, the
General Assignment and Assumption and the other Assignment Instruments, the
Assumption Instruments, the International Products Manufacturing Agreement, the
U.S. Product Agreement, the U.S. Product Manufacturing Agreement, the Transition
Services Agreement and any supporting, collateral or other agreements, consents
or approvals to be entered into or secured in connection with the foregoing or
the transactions contemplated herein and therein.
1.36 "PURCHASE PRICE" shall have the meaning set forth in
Section 2.3(a) herein.
1.37 "PURCHASER" shall have the meaning set forth in the
preamble.
1.38 "REGISTRATIONS" shall mean the International
Authorizations and the U.S. Authorizations.
1.39 "RETAINED LIABILITIES" shall have the meaning set forth
in Section 2.2(b) herein.
1.40 "SELLERS" shall have the meaning set forth in the
preamble.
4
<PAGE> 5
1.41 "SELLERS' PACKAGING MATERIALS" shall have the meaning set
forth in Section 2.6(b) herein.
5
<PAGE> 6
1.42 "SENIOR SUBORDINATED NOTES" shall have the meaning set
forth in Section 2.3(b) herein.
1.43 "SILVADENE" shall mean all formulations of the finished
product sold by Sellers which has as its active ingredient silver sulfadiazine.
1.44 "TRADEMARKS" shall mean the International Trademarks and
the U.S. Trademarks.
1.45 "TRANSITION SERVICES AGREEMENT" shall have the meaning
set forth in the Recitals.
1.46 "U.S. ASSUMED CONTRACTS" shall have the meaning set forth
in Section 2.1(b)(v) herein.
1.47 "U.S. AUTHORIZATIONS" shall have the meaning set forth in
Section 2.1(b)(ii) herein.
1.48 "U.S. PRODUCT" shall have the meaning set forth in the
Recitals.
1.49 "U.S. PRODUCT AGREEMENT" shall have the meaning set forth
in the Recitals.
1.50 "U.S. PRODUCT ASSETS" shall have the meaning set forth in
Section 2.1(b) herein.
1.51 "U.S. PRODUCT MANUFACTURING AGREEMENT" shall have the
meaning set forth in the Recitals.
1.52 "U.S. TERRITORY" shall have the meaning set forth in the
U.S. Product Agreement.
1.53 "U.S. TRADEMARKS" shall have the meaning set forth in
Section 2.1(b)(i) herein.
ARTICLE II
SALE OF ASSETS, CLOSING AND CERTAIN POST-CLOSING OBLIGATIONS
2.1 SALE OF ASSETS. On the Closing Date, and subject to the
terms and conditions of this Agreement, Sellers will sell, assign, convey,
transfer, and deliver to Purchaser, and Purchaser will purchase and accept from
Sellers, the following:
6
<PAGE> 7
(a) the following assets related to the International Products in the
International Territory (collectively, the "International Products
Assets"):
(i) all of Sellers' right, title, and interest in the
International Territory in and to the trademarks set forth on SCHEDULE
2.1(A)(I) attached hereto (collectively, the "International
Trademarks"), together with the goodwill of the business symbolized by
the International Trademarks in the International Territory;
(ii) all of Sellers' right, title, and interest in the
International Territory in and to the Know-How;
(iii) all of Sellers' right, title, and interest in and to the
regulatory approvals, licenses, applications and new drug applications
or abbreviated new drug applications and all supplements thereto, all
whether existing, pending, withdrawn or in draft form, together with
all correspondence to or from Governmental or Regulatory Authorities,
for the International Products, including those set forth on SCHEDULE
2.1(A)(III) attached hereto (the "International Authorizations");
(iv) subject to Section 2.6 of this Agreement, the trade dress
and logos, if any, associated with the International Products in the
International Territory, excluding any corporate or division name of
Sellers or their Affiliates, any logos of Sellers or their Affiliates,
any trademark (other than the International Trademarks or U.S.
Trademarks) of Sellers or their Affiliates and all NDC numbers of
Sellers or their Affiliates;
(v) the equipment relating to the manufacture and/or packaging of
AVC and Silvadene set forth on SCHEDULE 2.1(A)(V);
(vi) all historic sales data and customer lists (in each case to
the extent Sellers are not contractually or otherwise restricted or
prohibited from disclosing and/or granting rights therein) and
completed marketing and promotional plans and materials (excluding
samples of International Products), in each case which relate solely
to the International Products; and
(vii) all written contracts to which any Seller is a party and
which relate solely to Sellers' manufacture, packaging, marketing,
sale and distribution of International Products, including, without
limitation, all purchase orders and contracts relating to suppliers,
distributors, marketing arrangements and manufacturing and supply
arrangements, including, but not limited to, those contracts set forth
on SCHEDULE 2.1(A)(VII)(A) (the "International Assumed Contracts") and
excluding those contracts set forth on SCHEDULE 2.1(A)(VII)(B).
Written descriptions of those International Assumed Contracts
involving a payment by or to Sellers in a
7
<PAGE> 8
dollar amount greater than Fifty Thousand Dollars ($50,000) or under
which payments in the most recently completed calendar year exceed
Fifty Thousand Dollars ($50,000) in the aggregate and that cannot be
terminated within sixty (60) days after giving notice of termination
without resulting in any material cost or penalties to Purchaser are
set forth on SCHEDULE 2.1(A)(VII)(A).
(b) the following assets related to the U.S. Product in the U.S.
Territory (collectively, the "U.S. Product Assets"):
(i) all of Sellers' right, title, and interest in the U.S.
Territory in and to the trademarks set forth on SCHEDULE 2.1(B)(I)
attached hereto (collectively, the "U.S. Trademarks"), together with
the goodwill of the business symbolized by the U.S. Trademarks in the
U.S. Territory;
(ii) all of Sellers' right, title, and interest in and to the
regulatory approvals, licenses, applications , investigational new
drug applications and new drug applications and all supplements
thereto, all whether existing, pending, withdrawn or in draft form,
together with all correspondence to or from Governmental or Regulatory
Authorities, for the U.S. Product in the U.S. Territory including
those set forth on SCHEDULE 2.1(B)(II) attached hereto (the "U.S.
Authorizations");
(iii) subject to Section 2.6 of this Agreement, the trade dress
and logos, if any, associated with the U.S. Product in the U.S.
Territory, excluding any corporate or division name of Sellers or
their Affiliates, any logos of Sellers or their Affiliates, any
trademark (other than the U.S. Trademarks or International Trademarks)
of Sellers or their Affiliates and all NDC numbers of Sellers or their
Affiliates;
(iv) all historic sales data and customer lists (in each case to
the extent Sellers are not contractually or otherwise restricted or
prohibited from disclosing and/or granting rights therein) and
completed marketing and promotional plans and materials (excluding
samples of U.S. Product), in each case which relate solely to the U.S.
Product in the U.S. Territory;
(v) all written contracts to which any Seller is a party and
which relate solely to Sellers' manufacture, packaging, marketing,
sale and distribution of U.S. Product in the U.S. Territory,
including, without limitation, all purchase orders and contracts
relating to suppliers, distributors, marketing arrangements and
manufacturing and supply arrangements, including, but not limited to,
those contracts set forth on SCHEDULE 2.1(B)(V)(A) (the "U.S. Assumed
Contracts") and excluding those contracts set forth on SCHEDULE
2.1(B)(V)(B). Written descriptions of those U.S. Assumed Contracts
involving a payment by or to Sellers in a dollar amount
8
<PAGE> 9
greater than Fifty Thousand Dollars ($50,000) or under which payments
in the most recently completed calendar year exceeded Fifty Thousand
Dollars ($50,000) in the aggregate and that cannot be terminated
within sixty (60) days after giving notice of termination without
resulting in any material cost or penalties to Purchaser are set forth
on SCHEDULE 2.1(B)(V)(A); and
(vi) the rights and licenses granted under the U.S. Product
Agreement.
2.2 ASSUMED LIABILITIES.
(a) On the Closing Date, and subject to the terms and conditions of
this Agreement, Purchaser shall assume and agrees to pay, perform and
discharge when due the following liabilities and obligations of Sellers
arising in connection with the International Products in the International
Territory and the U.S. Product in the U.S. Territory (the "Assumed
Liabilities"):
(i) Obligations under the Assumed Contracts, Trademarks and
Registrations. All liabilities and obligations under the Assumed
Contracts, Trademarks and Registrations arising and to be performed on
or after the Closing Date.
(ii) Medicaid/Medicare Rebates; Chargebacks; Credits.
(A) State and federal Medicaid/Medicare rebates in
connection with the International Products in the United
States and U.S. Product in the U.S. Territory sold after the
Closing Date;
(B) Chargeback rebates and similar payments to
wholesalers and other distributors in connection with the
International Products in the International Territory and
U.S. Product in the U.S. Territory, beginning one (1) month
after the Closing Date; and
(C) Credits, utilization based rebates, reimbursements,
and similar payments to buying groups, insurers and other
institutions in connection with the International Products
in the International Territory and U.S. Product in the U.S.
Territory sold after the Closing Date
(iii) Recalls. From and after the Closing Date, all liabilities,
obligations and responsibilities relating to voluntary and involuntary
recalls of units of the International Products in the International
Territory (subject to the terms of the International Products
Manufacturing Agreement) sold by Purchaser after the
9
<PAGE> 10
Closing Date and units of the U.S. Product in the U.S. Territory
(subject to the terms of the U.S. Product Manufacturing Agreement)
sold by Purchaser after the Closing Date.
(iv) Products Liability. From and after the Closing Date, all
liabilities, obligations and responsibilities relating to product
liability claims or threatened claims relating to units of the
International Products in the International Territory (except as set
forth in the International Products Manufacturing Agreement) sold by
Purchaser after the Closing Date and units of the U.S. Product in the
U.S. Territory (except as set forth in the U.S. Product Manufacturing
Agreement) sold by Purchaser after the Closing Date.
(v) Research and Development; Sales and Marketing Activities.
Except as set forth in the Transition Services Agreement, all
liabilities, obligations and responsibilities for any research and
development and sales and marketing activities relating to any of the
International Products after the Closing Date and those liabilities,
obligations and responsibilities for research and development and
sales and marketing activities relating to the U.S. Product in the
U.S. Territory (i) set forth on SCHEDULE 2.2(A)(V) or (ii) conducted
by Purchaser after the Closing Date.
(vi) Returns. From and after the Closing Date, all liabilities
and obligations with respect to the returned units of International
Products in the International Territory and the U.S. Product in the
U.S. Territory, provided that Sellers shall reimburse Purchaser for
out-of-pocket payments made and expenses incurred, including, but not
limited to, the cost of credits given to the trade for returned
product, with respect to returns received regarding units of
International Products in the International Territory and U.S. Product
in the U.S. Territory sold prior to the Closing Date.
(b) Retained Liabilities. Except for the Assumed Liabilities and as
set forth in this Agreement or the Operative Agreements, Purchaser shall
not assume by virtue of this Agreement or any of the Operative Agreements
or the transactions contemplated hereby or thereby, and shall have no
liability for, any Losses of the Sellers of any kind, character or
description whatsoever or wheresoever (the "Retained Liabilities")
2.3 PURCHASE PRICE.
(a) Subject to the terms and conditions of this Agreement and the
terms and conditions of the Operative Agreements, Purchaser shall on the
Closing Date pay to Sellers as full and fair consideration for the Assets
and the entering into of the Operative Agreements, the sum of Three Hundred
Sixty-Two Million Five Hundred Thousand Dollars ($362,500,000) (the
"Purchase Price").
10
<PAGE> 11
(b) The Purchase Price shall be paid to Sellers at Closing by (i) wire
transfer of Two Hundred Eighty-Seven Million Five Hundred Thousand Dollars
($287,500,000) of immediately available funds to the accounts, and
allocated to each Seller, as specified in SCHEDULE 2.3(B) and (ii) delivery
of the senior subordinated promissory notes of Purchaser in the form of
EXHIBIT 5 hereto (the "Senior Subordinated Notes"), payable to Sellers in
the total aggregate principal amount of Seventy-Five Million Dollars
($75,000,000), the proceeds of which shall be allocated to each Seller as
specified in SCHEDULE 2.3(B); provided that:
(A) One Hundred Eighty-Seven Million Five Hundred Thousand
Dollars ($187,500,000) of the Purchase Price shall be paid to Sellers
at the time of Closing for the transfer of the Assets and the entering
into of the Operative Agreements and shall not be subject to any
further conditions; and
(B) One Hundred Seventy-Five Million Dollars ($175,000,000) of
the Purchase Price (the "Contingent Consideration") shall be paid to
Sellers at the time of Closing, but shall be contingent consideration
for the transfer of the Assets and the entering into of the Operative
Agreements subject to a refund to Purchaser from Sellers if the
aggregate gross sales of International Products in the International
Territory plus the aggregate gross sales of U.S. Product in the U.S.
Territory (together, the "Annual Aggregate Gross Sales") during each
of the calendar years 1999 and 2000 does not equal or exceed
Thirty-Seven Million Five Hundred Thousand Dollars ($37,500,000) for
each calendar year on a pro-rata basis in accordance with the
following formula: (A) one-half (1/2) the Contingent Consideration
minus (B) the product of (x) Annual Aggregate Gross Sales for such
calendar year divided by Thirty-Seven Million Five Hundred Thousand
Dollars ($37,500,000), multiplied by (y) one-half (1/2) the Contingent
Consideration; provided, however, such refund shall only be payable if
Purchaser has exerted commercially reasonable sales and promotional
efforts for the International Products in the International Territory
and U.S. Product in the U.S. Territory, consistent with the sales and
promotional efforts within the pharmaceutical industry for
pharmaceutical products of similar value.
(c) Any refund of the Contingent Consideration in accordance with
Section 2.3(b)(B) for calendar year 1999 shall be paid by Sellers to
Purchaser on or before June 30, 2000, and any refund of the Contingent
Consideration in accordance with Section 2.3(b)(B) for calendar year
2000 shall be paid by Sellers to Purchaser on or before June 30, 2001.
2.4 CLOSING.
11
<PAGE> 12
(a) The Closing will take place at the offices of HMRI in Kansas City,
Missouri, or at such other place as Purchaser and Sellers mutually agree,
at 10:00 A.M. Central Standard Time on the Closing Date.
(b) At the Closing, pursuant to the provisions of Section 2.3 above,
Purchaser will pay the Purchase Price. Simultaneously, (i) Sellers will
assign and transfer to Purchaser all of Sellers' right, title and interest
in and to the Assets, free and clear of all liens, claims, charges, or
encumbrances of any kind whatsoever, by delivery of (x) a General
Assignment, Assumption and Irrevocable Bill of Sale in the form of EXHIBIT
6 hereto (the "General Assignment and Assumption"), (y) an assignment of
the Trademarks in the form of EXHIBIT 7 hereto (the "Assignment of
Trademarks"), and (z) such other good and sufficient instruments of
conveyance, assignment and transfer, in form and substance reasonably
acceptable to Purchaser's counsel, as shall be effective to vest in
Purchaser good and valid title to the Assets (the General Assignment and
Assumption, the Assignment of Trademarks and such other instruments being
collectively referred to herein as the "Assignment Instruments"), and (ii)
Purchaser will assume from Sellers the due payment, performance and
discharge of the Assumed Liabilities by delivery of (x) the General
Assignment and Assumption, (y) the Assignment of Trademarks and (z) such
other good and sufficient instruments of assumption, in form and substance
reasonably acceptable to Sellers' counsel, as shall be effective to cause
Purchaser to assume the Assumed Liabilities (the General Assignment and
Assumption, the Assignment of Trademarks and such other instruments
collectively referred to herein as the "Assumption Instruments").
2.5 DELIVERY OF DOCUMENTATION. Sellers will, at their expense, deliver to
Purchaser's Executive Vice President, General Counsel, at the address as set
forth in Section 8.6(a) herein, copies of the materials comprising the Know-How,
the International Authorizations and the U.S. Authorizations, all in accordance
with a time frame and in a manner reasonably acceptable to the parties, but in
no event later than ninety (90) days after the Closing Date (provided that
Sellers shall have the right to retain one copy of such documents for their
archival purposes, or as necessary for Sellers to perform their obligations
under the Operative Agreements).
2.6 SCOPE OF PURCHASER'S RIGHTS.
(a) Purchaser acknowledges and agrees that Sellers and their
Affiliates shall be entitled to use the International Trademarks and the
Know-How after Closing to the extent necessary to fulfill Sellers'
obligations hereunder, under the International Products Manufacturing
Agreement, the U.S. Product Manufacturing Agreement and the Transition
Services Agreement, as applicable, or under applicable laws or regulations.
(b) The parties acknowledge that the International Products to be
supplied under the International Products Manufacturing Agreement and the
U.S. Product to be supplied under the U.S. Product Manufacturing Agreement
may contain packaging and
12
<PAGE> 13
labeling with the names, logos, trademarks and NDC numbers of Sellers and
their Affiliates ("Sellers' Packaging Materials"), and in that regard,
Sellers and their Affiliates agree to not withdraw any NDC numbers for the
International Products and U.S. Product for at least four (4) calendar
quarters after the expiration date of the last lot manufactured using any
such NDC number. Purchaser may distribute such International Products in
the International Territory and such U.S. Product in the U.S. Territory
with the Sellers' Packaging Materials; provided, however, Purchaser shall
not, and shall have no right to, use such names, logos, or trademarks for
any other purpose and Purchaser shall acquire no right, title, or interest
in or to such names, logos, and trademarks.
(c) Notwithstanding Section 2.6(b) above, Purchaser shall use its best
efforts to make all necessary arrangements as soon as possible so that
Purchaser will ship all International Products in the International
Territory and U.S. Product in the U.S. Territory without the use of any of
Sellers' Packaging Materials, including obtaining all necessary packaging
and labeling materials to do so and related regulatory approvals and, in
any event, by October 1, 1999, Purchaser shall distribute all such
International Products in the International Territory and U.S. Product in
the U.S. Territory without the use of any of Sellers' Packaging Materials
(except as required pursuant to the International Products Manufacturing
Agreement or the U.S. Product Manufacturing Agreement).
2.7 TAXES. Purchaser shall be responsible for and shall promptly pay all
federal, state, and local transfer, sales, and other taxes, if any, levied or
imposed as a result of the transactions contemplated by this Agreement,
excluding any tax payable on any income or gain of Sellers. All sums payable to
Sellers hereunder shall be paid in full and no deduction shall be made
therefrom, except that any withholding tax imposed in the United States upon
payments to be made by Purchaser or its Affiliates hereunder shall be borne by
Sellers up to the amount provided in the double taxation agreement existing
between the United States and the Federal Republic of Germany. Purchaser or its
Affiliates shall deduct such withholding tax from any payment made to Sellers
hereunder and shall promptly provide Sellers with the appropriate tax receipts.
The same shall apply mutatis mutandis to payments from Affiliates of Purchaser,
which are not incorporated in the United States.
2.8 ACTIONS BY THE PARTIES. Each of the parties shall use its best efforts
to take all actions and to do all things necessary, proper, or advisable in
order to consummate and make effective the transactions contemplated by this
Agreement, including, but not limited to, the satisfaction of the conditions to
closing of the parties set forth in Article V.
2.9 TERMINATION. This Agreement may be terminated at any time prior to
Closing:
(a) By mutual written consent of Purchaser and Sellers; or
13
<PAGE> 14
(b) By Purchaser or Sellers, upon written notice, at any time after
5:00 p.m. Central Standard Time on December 22, 1998, if at such time the
Closing has not been consummated.
2.10 INVENTORY. Immediately after the Closing, HMRI shall provide Purchaser
with a written inventory of units of International Products and units of U.S.
Product held in inventory by HMRI as of the Closing Date, and such inventory
shall be physically delivered to Purchaser with an invoice for the amount due
for such inventory (at prices for International Products in accordance with
EXHIBIT C of, and upon the other terms and conditions of, the International
Products Manufacturing Agreement and at prices for U.S. Product in accordance
with EXHIBIT C of, and upon the other terms and conditions of, the U.S. Product
Manufacturing Agreement), and payment shall be made in accordance with Article
III of the International Products Manufacturing Agreement and the U.S. Product
Manufacturing Agreement, as applicable.
2.11 RUGBY SUPPLY MATTERS.
(a) Purchaser hereby acknowledges that HMRI has granted certain
exclusive, perpetual license rights under the International Authorizations
covering Silvadene in the United States and its possessions and territories
to the generic versions of Silvadene ("Generic Silvadene") to The Rugby
Group, Inc., a New York corporation ("Rugby"), pursuant to that certain
Supply and License Agreement between HMRI and Rugby dated as of February
27, 1998 (the "Rugby Agreement"), a redacted copy of which has been
provided to Purchaser, and Purchaser hereby agrees that HMRI shall retain
those rights under the International Authorizations covering Silvadene in
the United States and its possessions and territories sufficient to enable
HMRI to continue to grant such exclusive license rights to Rugby on the
terms and conditions of the Rugby Agreement.
(b) During the period of time that HMRI manufactures Silvadene for
Purchaser pursuant to the International Products Manufacturing Agreement,
HMRI shall retain those rights with respect to Silvadene sufficient to
enable HMRI to manufacture and supply Generic Silvadene to Rugby on the
terms and conditions of the Rugby Agreement.
(c) Upon transfer of the manufacturing equipment to Purchaser pursuant
to the terms and conditions of the International Products Manufacturing
Agreement, HMRI shall assign all of its rights, and Purchaser shall assume
and undertake all of HMRI's obligations, to supply Generic Silvadene to
Rugby on the terms and conditions of the Rugby Agreement. HMRI shall not
agree to any change to the Rugby Agreement, from the form in which it has
been provided to Purchaser, which would impose any additional obligations
on Purchaser, without the prior written consent of Purchaser.
(d) The parties agree that they shall jointly develop a transition
plan to coordinate the transition of supply to Rugby from HMRI to King in
conjunction with the
14
<PAGE> 15
termination of the International Products Manufacturing Agreement and the
transfer of those Assets utilized in the manufacture of the International
Products in connection with such termination. HMRI agrees that it shall
hold any inventory required for supply to Rugby as may be required during
the supply transition.
ARTICLE III
REGULATORY MATTERS
3.1 FILINGS WITH GOVERNMENTAL OR REGULATORY AUTHORITIES REGARDING TRANSFER
OF REGISTRATIONS. Promptly after Closing, the parties shall file with the FDA
the information required pursuant to 21 C.F.R. ss.314.72, or any successor
regulation thereto, regarding the transfer of the Registrations from Sellers to
Purchaser. Sellers shall file the information required of a former owner, and
Purchaser shall file the information required of a new owner. The parties also
agree to use their best efforts to take any and all other actions required by
the FDA, or other necessary Governmental or Regulatory Authorities, if any, to
effect the transfer of the Registrations from Sellers to Purchaser. Sellers may
retain an archival copy of the Registrations, including supplements and records
that are required to be kept under 21 C.F.R. ss.314.81.
3.2 RESPONSIBILITY FOR THE INTERNATIONAL PRODUCTS AND U.S. PRODUCT.
(a) After the Closing, Purchaser shall assume all regulatory
responsibilities permitted by applicable laws and regulations to be assumed
by Purchaser, reporting and otherwise, in connection with the International
Products in the International Territory, the U.S. Product in the U.S.
Territory and the Registrations, including, but not limited to,
responsibility for reporting any adverse drug events in connection with the
Products, and responsibility for compliance with the Prescription Drug
Marketing Act of 1987, as the same may be amended from time to time.
(b) The parties will agree upon procedures to ensure a smooth
transition from Sellers to Purchaser of the activities required to be
undertaken by the holder of the Registrations, including, without
limitation, adverse experience reporting, quarterly and annual FDA reports,
complaint and sample tracking, and communication with health care
professionals and customers. Sellers agree to cooperate with Purchaser to
ensure a smooth transition of the activities contemplated hereby. Upon
completion of transfer of the Registrations to Purchaser, the procedures
for regulatory matters set forth in the International Products
Manufacturing Agreement shall be applicable to the International Products.
Upon completion of transfer of the U.S. Authorizations to Purchaser, the
procedures for regulatory matters set forth in the U.S. Product
Manufacturing Agreement shall be applicable to the U.S. Product.
(c) After the Closing, Purchaser shall assume all responsibility for
any and all fee obligations for holders or owners of approved new drug
applications and
15
<PAGE> 16
approved, marketed prescription drug products relating to the International
Products in the International Territory and the U.S. Product in the U.S.
Territory, including, but not limited to, those defined under the
Prescription Drug User Fee Act of 1992, as the same may be amended from
time to time.
(d) Promptly after the Closing, Purchaser and Sellers shall take all
actions necessary or required under applicable Laws to reflect that the
Assets are owned by Purchaser and that Purchaser has responsibility
therefor.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES
4.1 REPRESENTATIONS AND WARRANTIES OF SELLERS. Except to the extent such
representation or warranty is applicable to DV, Sellers represent and warrant to
Purchaser as follows:
(a) Organization and Standing. HMRI is a corporation and HMR GmbH is a
limited liability company, duly organized, validly existing, and, with
respect to HMRI, in good standing under the laws of the jurisdiction of its
incorporation or formation.
(b) Power and Authority. Each Seller has all requisite corporate or
limited liability company power and authority to execute, deliver, and
perform this Agreement and the other agreements and instruments to be
executed and delivered by it pursuant hereto and to consummate the
transactions contemplated herein and therein. The execution, delivery, and
performance of this Agreement by each Seller does not, and the consummation
of the transactions contemplated hereby will not, violate any provisions of
such Seller's organizational documents, bylaws, any law or regulation
applicable to Sellers, or any agreement, mortgage, lease, instrument,
order, judgment, or decree to which either Seller is a party or by which
such Seller is bound or result in the creation or acceleration of any lien
charge, security interest, or other encumbrance on the Assets.
(c) Corporate Action; Binding Effect. Each Seller has duly and
properly taken all action required by law, its organizational documents, or
otherwise, to authorize the execution, delivery, and performance of this
Agreement and the other instruments to be executed and delivered by it
pursuant hereto and the consummation of transactions contemplated hereby
and thereby. This Agreement has been duly executed and delivered by each
Seller and constitutes, and the other instruments contemplated hereby when
duly executed and delivered by each Seller will constitute, legal, valid,
and binding obligations of such Seller enforceable against it in accordance
with their respective terms, except as enforcement may be affected by
bankruptcy, insolvency, or other similar laws and by general principles of
equity.
16
<PAGE> 17
(d) Consents. Except with respect to the pre-merger notification
report under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the
"H-S-R Act") and the consents set forth on SCHEDULE 4.1(D), no consent or
approval of, or filing with or notice to, any Governmental or Regulatory
Authority or any other person not a party to this Agreement is required or
necessary to be obtained by either Seller or on its behalf in connection
with the execution, delivery, and performance of this Agreement or to
consummate the transactions contemplated hereby, except as contemplated by
Section 3.1 hereof or which has been obtained prior to the execution of
this Agreement or which would not, either individually or cumulatively,
have a material adverse effect on the Assets or Sellers' performance
hereunder.
(e) Ownership of Assets. Sellers are the owners of the Assets
described in Sections 2.1(a)(i) and (iii)-(vii) and 2.1(b), and, to
Sellers' knowledge, the Assets described in Section 2.1(a)(ii), and the
Assets are free and clear of all liens, claims, charges, or encumbrances,
except for liens for taxes not yet due and payable and except as described
on SCHEDULE 4.1(E) attached hereto.
(f) Litigation or Disputes. Except as disclosed in SCHEDULE 4.1(F)
attached hereto, there is no claim, outstanding commitment to any
governmental regulatory agency, action, suit, proceeding, investigation, or
arbitration pending or, to Sellers' knowledge, threatened against Sellers
relating to the Assets, and Sellers are not in violation of or in default
with respect to any applicable law, rule, regulation, judgment, order,
writ, injunction, award, or decree of any arbitrator, court, or
administrative body, the result of any of which, either individually or
cumulatively, would have a materially adverse effect on the International
Assets in the International Territory or the U.S. Assets in the U.S.
Territory or Sellers' compliance with and performance under the terms of
this Agreement or the Operative Agreements contemplated hereby or thereby.
(g) Trademarks; Intellectual Property.
(i) SCHEDULE 2.1(A)(I) attached hereto is a true and correct list
of all trademarks owned by Sellers and used by Sellers in the
manufacture, marketing, and sale of the International Products in the
International Territory.
(ii) SCHEDULE 2.1(B)(I) attached hereto is a true and correct
list of all trademarks owned by Sellers and used by Sellers in the
manufacture, marketing, and sale of the U.S. Product in the U.S.
Territory.
(iii) The International Trademarks are the only trademarks used
or held by Sellers for use in connection with or otherwise necessary
for the conduct of Sellers' business as now conducted for the
International Products in the International Territory.
17
<PAGE> 18
(iv) The U.S. Trademarks are the only trademarks used or held by
Sellers for use in connection with or otherwise necessary for the
conduct of Sellers' business as now conducted for the U.S. Product in
the U.S. Territory.
(v) Sellers neither own nor have licenses to any patents with
valid claims covering the conduct of Sellers' business as now
conducted for the International Products in the International
Territory.
(vi) Sellers or their Affiliates have not received any notice of
any claim that any of the Assets infringe on any property rights of
any other party. There is no claim, action, suit, or proceeding,
pending or, to Sellers' knowledge, threatened alleging that the use by
Sellers or its Affiliates of the International Trademarks or the
Know-How infringes any patents or other intellectual property rights
of third parties.
(vii) Except as set forth on SCHEDULE 4.1(G)(VII), Sellers have
not executed or granted to any Affiliate or any third party any
license, sublicense, or contract covering the Know-How or the
International Trademarks in the United States or the U.S. Trademarks
in the U.S. Territory.
(h) Compliance with Laws. To Sellers' knowledge, Sellers have
conducted their operations in connection with the manufacture and sale of
the International Products in the International Territory and the U.S.
Product in the U.S. Territory in material compliance with all applicable
Laws of Governmental or Regulatory Authorities, and possess all approvals,
consents, licenses, and permits required for (i) the conduct of their
business as now conducted for the International Products in the
International Territory or as will be necessary for HMRI to perform its
obligations under the International Products Manufacturing Agreement and
(ii) the conduct of their business as now conducted for the U.S. Product in
the U.S. Territory or as will be necessary to perform their obligations
under the U.S. Product Manufacturing Agreement.
(i) Contracts. With respect to each Assumed Contract required to be
disclosed on SCHEDULE 2.1(A)(VII)(A) or SCHEDULE 2.1(B)(V)(A) to which
either Seller is a party, and except as disclosed on SCHEDULE 4.1(I): (i)
no Seller is in material breach of or default under any Assumed Contract,
and to Sellers' knowledge, no event has occurred which with the passage of
time or giving of notice or both would constitute such a default, result in
a material loss of benefits or rights or result in the creation of any
material lien, charge, claim, security interest or encumbrance, thereunder
or pursuant thereto; (ii) to Sellers' knowledge, there is no existing
material breach or default by any other party to any Assumed Contract;
(iii) to Sellers' knowledge, no event has occurred which with the passage
of time or giving notice of or both would constitute such a default by such
other party, result in a material loss of rights or result in the creation
of any lien, charge or encumbrance, thereunder or pursuant thereto; and
(iv) the continuation, validity and effectiveness of each Assumed
18
<PAGE> 19
Contract would not be affected by the transfer thereof to the Purchaser
under this Agreement and all such Assumed Contracts are either assignable
to the Purchaser without consent or any such necessary consent has been
obtained prior to the execution of this Agreement.
(j) Recalls or Withdrawals. During the period commencing on December
31, 1995, and ending on the date hereof, there have been no:
(i) units of International Products which have been recalled or
withdrawn by Sellers or their Affiliates in the United States (whether
voluntarily or otherwise);
(ii) proceedings in the United States brought against Sellers or
their Affiliates (whether such proceedings have since been completed
or remain pending) seeking the recall, withdrawal, or seizure of any
of the International Products or seeking to enjoin Sellers or any of
their Affiliates from distributing such International Products;
(iii) units of U.S. Product which have been recalled or withdrawn
by Sellers or their Affiliates in the U.S. Territory (whether
voluntarily or otherwise); or
(iv) proceedings in the U.S. Territory brought against Sellers or
their Affiliates (whether such proceedings have since been completed
or remain pending) seeking the recall, withdrawal, or seizure of any
U.S. Product or seeking to enjoin Sellers or any of their Affiliates
from distributing such U.S. Product.
(k) Facilities and Manufacture.
(i) Except as set forth on SCHEDULE 4.1(K)(I) attached hereto,
and only to the extent it could have a material adverse effect on the
Assets or Sellers' performance hereunder or under any of the
agreements contemplated hereby, during the period commencing on
December 31, 1995, and ending on the date hereof, with respect only to
the International Products in the United States, neither Sellers nor
their Affiliates have received or been subject to: (i) any FDA Form
483's relative to the International Products; (ii) any FDA Notices of
Adverse Findings relative to the International Products, or (iii)
warning letters or other correspondence from the FDA or any other
Governmental or Regulatory Authority concerning the International
Products in which the FDA or other such Governmental or Regulatory
Authority asserted that the operations of Sellers were not in
compliance with applicable Laws.
(ii) Except as set forth on SCHEDULE 4.1(K)(II) attached hereto,
and only to the extent it could have a material adverse effect on the
Assets or Sellers'
19
<PAGE> 20
performance hereunder or under any of the agreements contemplated
hereby, during the period commencing on September 1, 1997, and ending
on the date hereof, with respect only to the U.S. Product in the U.S.
Territory, neither Sellers nor their Affiliates have received or been
subject to: (i) any FDA Form 483's relative to the U.S. Product; (ii)
any FDA Notices of Adverse Findings relative to the U.S. Product, or
(iii) warning letters or other correspondence from the FDA or any
other Governmental or Regulatory Authority concerning the U.S. Product
in which the FDA or other such Governmental or Regulatory Authority
asserted that the operations of Sellers were not in compliance with
applicable Laws.
(iii) Except as set forth on SCHEDULE 4.1(K)(III) attached
hereto, and only to the extent it could have a material adverse effect
on the Assets or Sellers' performance hereunder or under any of the
agreements contemplated hereby, during the period commencing on
December 31, 1995, and ending on the date hereof, no employees of
Sellers have been debarred under ss.306(a) or ss.306(b) of the Federal
Food, Drug and Cosmetic Act or been convicted of or formally charged
with a criminal offense relating to the development or approval
process of any drug product.
(l) Conduct of Business.
(i) Except as disclosed to Purchaser, since December 31, 1995,
Sellers have conducted their business relating to the International
Products in the United States and the U.S. Product in the U.S.
Territory in the ordinary course of business in all material respects
and, since December 31, 1995, through the date hereof, Sellers have
not offered any extraordinary rebates, discounts, or any other
promotion or marketing incentives relating to the International
Products in the United States or the U.S. Product in the U.S.
Territory, in each case other than in the ordinary course of business.
(ii) To Sellers' knowledge, Sellers have maintained, and continue
to maintain, with respect to the business of the U.S. Product in the
U.S. Territory, good working relationships with their material
suppliers of active and inactive ingredients, packaging materials and
components and marketing services.
(m) Condition of Equipment. The Assets set forth on SCHEDULE 2.1(A)(V)
are, and at the time of Closing will be, in working order and in a
condition expected for equipment of such age and type, subject to normal
wear and maintenance.
(n) Disclosure. To Sellers' knowledge, no representation or warranty
of Sellers contained in this Agreement and no information contained in any
schedule hereto contains or will contain any untrue statement or omits or
will omit to state a material fact
20
<PAGE> 21
necessary in order to make the statements made herein or therein, in light
of the circumstances under which they were made, not materially misleading.
4.2 REPRESENTATIONS AND WARRANTIES OF PURCHASER. Purchaser represents and
warrants to Sellers as follows:
(a) Organization and Standing. Purchaser is a corporation duly
organized, validly existing and in good standing under the laws of the
State of Tennessee.
(b) Power and Authority. Purchaser has all requisite corporate power
and authority to execute, deliver, and perform this Agreement, and the
other agreements and instruments to be executed and delivered by it
pursuant hereto and to consummate the transactions contemplated herein and
therein. The execution, delivery, and performance of this Agreement by
Purchaser do not, and the consummation of the transactions contemplated
hereby will not, violate any provision of Purchaser's articles of
incorporation, bylaws, any law or regulation applicable to Purchaser, or
any agreement, mortgage, lease, instrument, order, judgment, or decree to
which Purchaser is a party or by which Purchaser is bound, except as
consent to this Agreement and the transactions contemplated hereby may be
required under Purchaser's agreements with its lenders which consent shall
have been obtained at or prior to the Closing.
(c) Corporate Action; Binding Effect. Purchaser has duly and properly
taken all action required by law, its articles of incorporation, its
bylaws, or otherwise, to authorize the execution, delivery, and performance
by it of this Agreement and the other instruments to be executed by it
pursuant hereto and the consummation of the transactions contemplated
hereby and thereby. This Agreement has been duly executed and delivered by
Purchaser and constitutes, and the other instruments contemplated hereby
when duly executed and delivered by Purchaser will constitute, legal,
valid, and binding obligations of Purchaser enforceable against it in
accordance with their respective terms, except as enforcement may be
affected by bankruptcy, insolvency, or other similar laws and by general
principles of equity.
(d) Consents. Except with respect to the pre-merger notification
report filed under the H-S-R Act, no consent or approval of, or filing with
or notice to, any federal, state, or local governmental or regulatory
authority, agency, or department or any other person not a party to this
Agreement is required or necessary to be obtained by Purchaser or on its
behalf in connection with the execution, delivery, and performance of this
Agreement or to consummate the transactions contemplated hereby, except as
contemplated by Section 3.1 hereof or which have been obtained prior to the
execution of this Agreement, except as consent to this Agreement and the
transactions contemplated hereby may be required under Purchaser's
agreements with its lenders which consent shall have been obtained at or
prior to the Closing.
21
<PAGE> 22
4.3 SURVIVAL OF REPRESENTATIONS/WARRANTIES. The representations and
warranties contained in this Article IV and the indemnification with respect
thereto pursuant to Article VI shall survive the Closing Date for a period of
two (2) years, except that Section 4.1(e) (Ownership of Assets) and the
indemnification with respect thereto pursuant to Article VI shall survive the
Closing Date for a period of three (3) years.
4.4 BROKERS. Each party hereby represents that all negotiations relative to
this Agreement and the transactions contemplated hereby have been carried out by
each such party directly with the other party without the intervention of any
third party on behalf of either party in such manner as to give rise to any
valid claim by any third party against either party for a finder's fee,
brokerage commission or similar payment.
4.5 FINANCING. Purchaser has sufficient cash and or available credit
facilities (and has provided Sellers with evidence thereof in the form of a
guaranteed commitment letter from Credit Suisse First Boston, First Union
National Bank and NationsBank, N.A.) to pay the Purchase Price and to make all
other necessary payments of fees and expenses in connection with the
transactions contemplated by this Agreement and the Operative Agreements.
4.6 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED HEREIN, SELLERS
DISCLAIM ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO THE
INTERNATIONAL PRODUCTS AND THE U.S. PRODUCT, INCLUDING, BUT NOT LIMITED TO, THE
WARRANTY OF MERCHANTABILITY AND THE WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE.
ARTICLE V
CONDITIONS TO CLOSING
5.1 CONDITIONS TO OBLIGATIONS OF PURCHASER. The obligations of Purchaser
hereunder to consummate the transactions contemplated by this Agreement are
subject to the fulfillment, at or before the Closing, of each of the following
conditions (all or any of which may be waived in whole or in part by Purchaser,
but only in writing, in its sole discretion):
(a) Representations and Warranties. The representations and warranties
made by Sellers in this Agreement and the Operative Agreements shall be
materially true and correct on and as of the Closing Date as though made on
and as of the Closing Date or, in the case of representations and
warranties made as of a specified date earlier than the Closing Date, on
and as of such earlier date.
(b) Performance. Sellers shall have performed and complied with, in
all material respects, the agreements and obligations required by this
Agreement and the
22
<PAGE> 23
Operative Agreements to be so performed or complied with by Seller at or
before the Closing.
(c) Orders and Laws. There shall not be in effect on the Closing Date
any judgment, order, decree, ruling or charge restraining, enjoining or
otherwise prohibiting or making illegal the consummation of any of the
transactions contemplated by this Agreement or any of the Operative
Agreements.
(d) H-S-R Act. All applicable waiting periods (and any extensions
thereof) under the H-S-R Act shall have expired or otherwise been
terminated.
(e) Deliveries. Sellers shall have executed, as applicable, and
delivered to Purchaser:
(i) the Assignment Instruments;
(ii) the U.S. Product Agreement;
(iii) the U.S. Product Manufacturing Agreement;
(iv) the International Products Manufacturing Agreement;
(v) the Transition Services Agreement; and
(vii) such other documents, materials and instruments reasonably
requested by Purchaser as may be necessary to completely sell and
assign the Assets and transfer the Assumed Liabilities to Purchaser.
(f) Financial Statements. Sellers shall have delivered, or caused to
be delivered, to Purchaser, audited financial statements covering sales of
Silvadene and AVC in the United States and the U.S. Product in the U.S.
Territory for the calendar years ended December 31, 1996 and December 31,
1997 and for the first three calendar quarters of 1998.
5.2 CONDITIONS TO OBLIGATIONS OF SELLERS. The obligations of Sellers
hereunder to consummate the transactions contemplated by this Agreement are
subject to the fulfillment, at or before the Closing, of each of the following
conditions (all or any of which may be waived in whole or in part by Sellers,
but only in writing, in their sole discretion):
(a) Representations and Warranties. The representations and warranties
made by Purchaser in this Agreement and the Operative Agreements shall be
true and correct in all material respects on and as of the Closing Date as
though made on and as of the
23
<PAGE> 24
Closing Date or, in the case of representations and warranties made as of a
specified date earlier than the Closing Date, on and as of such earlier
date.
(b) Performance. Purchaser shall have performed and complied with, in
all material respects, the agreements and obligations required by this
Agreement and the Operative Agreements to be so performed or complied with
by Purchaser at or before the Closing.
(c) Orders and Laws. There shall not be in effect on the Closing Date
any judgment, order, decree, ruling or charge restraining, enjoining or
otherwise prohibiting or making illegal the consummation of any of the
transactions contemplated by this Agreement or any of the Operative
Agreements.
(d) H-S-R Act. All applicable waiting periods (and any extensions
thereof) under the H-S-R Act shall have expired or otherwise been
terminated.
(e) Deliveries. Purchaser shall have executed and delivered to
Sellers:
(i) the Assumption Instruments;
(ii) the U.S. Product Agreement;
(iii) the U.S. Product Manufacturing Agreement;
(iv) the International Products Manufacturing Agreement;
(v) the Transition Services Agreement;
(vi) the Senior Subordinated Notes (together with an opinion of
counsel in a form reasonably acceptable to Sellers regarding
authority, execution, validity and absence of conflict); and
(vii) such other documents, materials and instruments reasonably
requested by Sellers as may be necessary to completely sell and assign
the Assets and transfer the Assumed Liabilities to Purchaser.
(f) Note Purchase Agreements. Purchaser shall have caused each of the
parties thereto to execute and deliver to Sellers the Note Purchase
Agreements in the form attached hereto as EXHIBIT 8 (the "Note Purchase
Agreements") pursuant to which the parties thereto shall, upon the terms
specified therein, purchase the Senior Subordinated Notes (together with an
opinion of counsel in a form reasonably acceptable to Sellers).
24
<PAGE> 25
(g) Letters of Credit. Purchaser shall have caused each of the parties
thereto to execute and deliver to Sellers one or more Letters of Credit in
the form attached hereto as EXHIBIT 9 (the "Letters of Credit"), and
covering in their entirety Purchaser's obligation to make interest payments
under the Senior Subordinated Notes.
ARTICLE VI
INDEMNIFICATION
6.1 INDEMNIFICATION.
(a) Subject to Section 6.1(c) of this Section 6.1 and the other
Sections of this Article VI, Sellers shall indemnify Purchaser and its
officers, directors, employees, agents and Affiliates in respect of, and
hold each of them harmless from and against, any and all Losses suffered,
incurred or sustained by any of them or to which any of them becomes
subject, resulting from, arising out of or relating to:
(i) Any Retained Liability of Sellers, including, but not limited
to, product liability claims or threatened claims relating to the U.S.
Product sold by Purchaser prior to the Closing Date and claims
alleging patent infringement or other third party claims out of the
exercise by Sellers prior to the Closing Date of the licenses to
Patent Rights, Schering Patent Rights and Ramipril Know-How (as such
terms are defined in the U.S. Product Agreement) granted pursuant to
the U.S. Product Agreement;
(ii) Misrepresentation or breach of warranty or covenant or
agreement by Sellers made or contained in this Agreement, the U.S.
Product Agreement or in any Exhibit, Schedule, certificate or other
instrument furnished or to be furnished to the Purchaser under this
Agreement or the U.S. Product Agreement;
(iii) Litigation or other claims arising from acts, failures to
act or events relating to the Assets which occurred prior to the
Closing Date; and
(iv) The use of the Assets before the Closing Date.
Notwithstanding any provision herein or in the U.S. Product Agreement
to the contrary, the parties agree that in no event will Sellers be liable
to Purchaser for special, consequential, indirect, punitive or similar
damages.
(b) Subject to Section 6.1(c) of this Section 6.1 and the other
Sections of this Article VI, Purchaser shall indemnify Sellers and their
respective officers, directors, employees, agents and Affiliates in respect
of, and hold each of them harmless from and
25
<PAGE> 26
against, any and all Losses suffered, incurred or sustained by any of
them or to which any of them becomes subject, resulting from, arising out
of or relating to:
(i) The Assumed Liabilities;
(ii) Misrepresentation or breach of warranty or covenant or
agreement by the Purchaser made or contained in this Agreement, the
U.S. Product Agreement or in any Exhibit, Schedule, certificate or
other instrument furnished or to be furnished to Sellers under this
Agreement or the U.S. Product Agreement;
(iii) Litigation or other claims arising from acts, failures to
act or events relating to the Assets which occurred on or after the
Closing Date;
(iv) The use of the Assets on or after the Closing Date; and
(v) Product liability claims or threatened claims relating to the
Licensed Products (as such term is defined in the U.S. Product
Agreement) sold by Purchaser after the Closing Date and claims
alleging patent infringement or other third party claims out of the
exercise by Purchaser of the licenses to Patent Rights, Schering
Patent Rights and Ramipril Know-How (as such terms are defined in the
U.S. Product Agreement) granted pursuant to the U.S. Product
Agreement.
Notwithstanding any provision herein or in the U.S. Product Agreement
to the contrary, the parties agree that in no event will Purchaser be
liable to Sellers for special, consequential, indirect, punitive or similar
damages.
(c) Notwithstanding anything to the contrary contained in this
Agreement, no amounts of indemnity shall be payable as a result of any
claim in respect of a Loss arising under paragraph (a) or (b) of Section
6.1:
(i) unless, until and then only to the extent that the
Indemnified Parties thereunder have suffered, incurred, sustained or
become subject to Losses referred to in such paragraphs in excess of
One Hundred Thousand Dollars ($100,000) in the aggregate;
(ii) with respect to any Loss, to the extent that the party
seeking indemnification had a reasonable opportunity, but failed, in
good faith to mitigate the Loss, including, but not limited to, the
failure to use commercially reasonable efforts to recover under such
party's policy of insurance or under a contractual right of set-off or
indemnity; or
26
<PAGE> 27
(iii) with respect to any Loss, to the extent that such Loss is
caused by (a) any inaccuracy of a representation or breach of a
warranty made by the party seeking indemnification in the Agreement or
(b) the gross negligence or intentional misconduct of such party or
any of its officers, directors, employees, agents or Affiliates.
(d) The limitations contained in clause (i) of Section 6.1(c) shall
not apply to Losses arising from breach of Purchaser's and Sellers'
respective obligations hereunder with respect to Assumed Liabilities and
Retained Liabilities.
(e) Notwithstanding any provision in this Agreement to the contrary,
the maximum amount of Losses for which Sellers may be liable under this
Article VI shall not exceed (i) Forty Million Dollars ($40,000,000) for any
such Losses relating to the International Products (excluding DV), (ii)
Three Hundred Twenty-Two Million Five Hundred Thousand Dollars
($322,500,000) for any such Losses relating to the U.S. Product, or (iii)
Three Hundred Sixty-Two Million Five Hundred Thousand Dollars
($362,500,000) in the aggregate. Sellers shall not be liable under this
Article VI for any Losses relating to DV.
6.2 METHOD OF ASSERTING CLAIMS. A party (the "Indemnitee") that intends to
claim indemnification under this Article VI shall:
(a) notify the other party (the "Indemnitor") of any Losses with
respect to which the Indemnitee intends to claim indemnification as soon as
practicable after the Indemnitee becomes aware of any such Losses;
(b) permit the Indemnitor to assume the defense thereof with counsel
mutually satisfactory to the parties; and
(c) cooperate with the Indemnitor, at the Indemnitor's expense, in the
defense thereof.
With respect to any matter for which the Indemnitor has an obligation to
indemnify the Indemnitee under this Agreement, the Indemnitee shall have the
right to participate and be represented (at the Indemnitor's expense) by legal
counsel of the Indemnitee's choice in all proceedings and negotiations, if
representation by counsel retained by Indemnitor would be inappropriate due to
actual or potential differing interests between the Indemnitee and any other
party represented by such counsel in such proceedings. The indemnity agreement
in this Article VI shall not apply to amounts paid in settlement of any Losses
if such settlement is effected without the consent of the Indemnitor, which
consent shall not be unreasonably withheld. Failure of the Indemnitee to deliver
notice to the Indemnitor within a reasonable time after becoming aware of a
27
<PAGE> 28
potential Loss shall not relieve the Indemnitor of any liability to the
Indemnitee pursuant to this Article VI, except to the extent such delay
prejudices the Indemnitor's ability to defend such action.
ARTICLE VII
DISPUTE RESOLUTION
7.1 DISPUTE RESOLUTION.
(a) Any dispute, controversy or claim arising out of or relating to
this Agreement, or the breach, termination, or invalidity of this Agreement
shall be submitted in the first instance to the Chief Operating Officer of
HMRI, or such person's designee of equivalent or superior position, and the
Chief Operating Officer of Purchaser, or such person's designee of
equivalent or superior position.
(b) If the matter or dispute cannot be resolved by the individuals
designated in Section 7.1(a) within thirty (30) days after such submission,
it shall be settled by arbitration in accordance with the Commercial
Arbitration Rules of the American Arbitration Association, except as
modified by this section. The number of arbitrators shall be three (3), one
(1) of whom is selected by Purchaser, one (1) of whom is selected by
Sellers and one (1) of whom is selected by Sellers and Purchaser (or by the
other two (2) arbitrators if the parties cannot agree). The arbitration
proceeding shall be conducted in the English language. The arbitration
proceeding shall be brought in New York, New York, unless the parties agree
in writing to conduct the arbitration in another location.
(c) The arbitration decision shall be binding and not be appealable to
any court in any jurisdiction. The prevailing party may enter such decision
in any court having competent jurisdiction.
(d) Each party shall pay its own expenses of arbitration and the
expenses of the arbitrators shall be equally shared except that if, in the
opinion of the arbitrators, any claim by a party hereto or any defense or
objection thereto by the other party was unreasonable, the arbitrators may
in their discretion assess as part of the award any part of the arbitration
expenses of the other party (including reasonable attorneys' fees) and
expenses of the arbitrators against the party raising such unreasonable
claim, defense or objection.
(e) Any party may, without inconsistency with this Agreement, apply to
any court having jurisdiction hereof and seek injunctive relief so as to
maintain the status quo until such time as the arbitration award is
rendered or the controversy is otherwise resolved.
28
<PAGE> 29
ARTICLE VIII
GENERAL PROVISIONS
8.1 NON-SOLICITATION. Unless Sellers otherwise agree in writing, from the
date of this Agreement and until December 31, 2000, Purchaser agrees not to, and
to cause its Affiliates not to, recruit, directly or indirectly, any person who
as of the date of this Agreement is an employee of either Seller or their
respective Affiliates or who was employed by either Seller or an Affiliate at
any time during the six months prior to such date, for employment with, or as a
consultant to, Purchaser or its Affiliates.
8.2 PAYMENT OF TRANSACTION EXPENSES. All legal fees and other expenses
incurred on behalf of Sellers in connection with the negotiation of this
Agreement and the consummation of the transactions contemplated herein will be
borne by Sellers; and all legal fees and other expenses incurred on behalf of
Purchaser in connection with the negotiation of this Agreement and the
consummation of the transactions contemplated herein will be borne by Purchaser.
8.3 ACCESS TO INFORMATION. After the Closing, Purchaser agrees to cooperate
with Sellers and to grant to Sellers and their employees, attorneys,
accountants, officers, representatives, and agents, during normal business hours
and upon ten (10) days' advance notice, reasonable access to Purchaser's
management personnel and to the records relating to the International Products
and the U.S. Product (including, without limitation, the Registrations) and to
permit copying at Sellers' expense or, where reasonably necessary, to loan
original documents relating to the Assets during the period the Assets were
owned by Sellers for the sole purposes of (i) any financial reporting or tax
matters (including, without limitation, any financial and tax audits, tax
contests, tax examination, preparation of any Sellers' tax returns or financial
records) relating to the International Products or U.S. Product; (ii) any claims
or litigation involving Sellers and the Assets relating to the International
Products or U.S. Product; (iii) any investigation of Sellers being conducted by
any federal, state, or local governmental authority relating to the
International Products or the U.S. Product; (iv) any matter relating to any
indemnification or representation or warranty or any other term of this
Agreement, or (v) any similar or related matter. Purchaser shall maintain, for
the extent required by applicable Law, but in any event for not less than six
(6) years, all such records and documents in the United States and shall not
destroy or dispose of any such records and documents prior to the end of such
required or six (6) year period, as the case may be, without the prior written
consent of Sellers. Sellers shall use their reasonable efforts to ensure that
its access to and requests for records and documents pursuant to this Section
8.3 are conducted so as not to interfere with the normal and ordinary operation
of Purchaser's business. Sellers acknowledge that the records and documents made
available to Sellers by Purchaser pursuant to this Section 8.3 constitute
confidential information of Purchaser and disclosure of such information shall
be governed by the confidentiality and non-disclosure provisions of the
International Products Manufacturing Agreement if related to an International
Product or the provisions of the U.S. Product Manufacturing Agreement if related
to a U.S. Product.
8.4 DELIVERY OF ASSETS; REMOVAL OF PROPERTY. Subject to the terms and
conditions of this Agreement and the Operative Agreements, on the Closing Date,
Sellers will take
29
<PAGE> 30
all commercially reasonable steps to deliver or make available to Purchaser the
Assets in Sellers' possession (including, those Assets described on SCHEDULE
2.1(A)(V) hereto pursuant to the terms of the International Products
Manufacturing Agreement), and if at any time after the Closing Date, Sellers
discover in their possession or in the possession of their Affiliates or under
their control or the control of their Affiliates any other such Assets, it will
forthwith deliver same at its expense to Purchaser.
8.5 NO OTHER REPRESENTATIONS. Notwithstanding anything to the contrary
contained in this Agreement, it is the explicit intent of each party hereto that
neither Sellers nor Purchaser are making any representation or warranty
whatsoever, express or implied, including, but not limited to, any implied
representation or warranty as to condition, merchantability or suitability as to
any of the Assets, except those representations and warranties contained in
Article IV of this Agreement and in the U.S. Product Agreement, and the
Schedules and Exhibits hereto and thereto. In particular, Sellers do not make
any representation or warranty to Purchaser with respect to (i) the information
set forth in the offering materials provided to the Purchaser by Sellers or (ii)
any financial projection or forecast relating to the business prospects for the
International Products or the U.S. Product. With respect to any projection or
forecast delivered by or on behalf of any Seller to Purchaser, Purchaser
acknowledges that (i) there are uncertainties inherent in attempting to make
such projections and forecasts, (ii) it is familiar with such uncertainties,
(iii) it is taking full responsibility for making its own evaluation of the
adequacy and accuracy of all such projections and forecasts furnished to it and
(iv) it shall have no claim against Sellers with respect to such projections and
forecasts prepared in good faith by Sellers.
8.6 NOTICES.
(a) Except as otherwise specifically provided herein, any notice or
other documents to be given under this Agreement shall be in writing and
shall be deemed to have been duly given if sent by registered post,
nationally recognized overnight courier or facsimile transmission to a
party or delivered in person to a party at the address or facsimile number
set out below for such party or such other address as the party may from
time to time designate by written notice to the other:
If to Purchaser, to:
King Pharmaceuticals, Inc.
501 Fifth Street
Bristol, Tennessee 37620
Attn: Chairman of the Board
Facsimile: 423-989-8006
30
<PAGE> 31
with copies to:
King Pharmaceuticals, Inc.
501 Fifth Street
Bristol, Tennessee 37620
Attn: Executive Vice President and General Counsel
Facsimile: 423-989-6282
and
Monarch Pharmaceuticals, Inc.
355 Beecham Street
Bristol, TN 37620
Attn: Chief Executive Officer
Facsimile: 423-989-8006
If to Sellers, to:
Hoechst Marion Roussel, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137
Attn: President
Facsimile: 816-966-3152
and
Hoechst Marion Roussel Deutschland GmbH
Konigsteiner Strasse 10
Germany
Attn: General Manager
Facsimile: 49-69-305-17905
with copies to:
Hoechst Marion Roussel, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137
Attn: General Counsel, North America
Facsimile: 816-966-3805
and
31
<PAGE> 32
Hoechst Marion Roussel Deutschland GmbH
Konigsteiner Strasse 10
Germany
Attn: Legal Department
Facsimile: 49-69-305-15096
(b) Any such notice or other document shall be deemed to have been
received by the addressee five (5) business days following the date of
dispatch of the notice or other document by post or, where the notice or
other document is sent by overnight courier, by hand or is given by
facsimile, simultaneously with the transmission or delivery. To prove the
giving of a notice or other document it shall be sufficient to show that it
was dispatched.
8.7 ENTIRE AGREEMENT; AMENDMENT.
(a) This Agreement, together with the Operative Agreements and the
Exhibits and Schedules attached hereto and thereto, embodies and sets forth
the entire agreement and understanding of the parties with respect to the
subject matter herein and therein and there are no promises, terms,
conditions or obligations, oral or written, expressed or implied, other
than those contained herein and therein. The terms of this Agreement shall
supersede all previous oral or written agreements which may exist or have
existed between the parties relating to the subject matter of this
Agreement. No party shall be entitled to rely on any agreement,
understanding or arrangement which is not expressly set forth in this
Agreement. Any other terms and conditions (including without limitation any
terms and conditions contained in any purchase order or sales invoice
issued pursuant to the Operative Agreements) are hereby expressly excluded.
(b) This Agreement shall not be amended, modified, varied or
supplemented except in writing signed by duly authorized representatives of
the parties.
8.8 FORCE MAJEURE. If a party is prevented or delayed in the performance of
any of its obligations under this Agreement by Force Majeure (as defined herein)
and shall give written notice thereof to the other party specifying the matters
constituting Force Majeure together with such evidence as such party reasonably
can give and specifying the period for which it is estimated that such
prevention or delay will continue, the party shall be excused from the
performance or the punctual performance of such obligations as the case may be
from the date of such notice for so long as such cause of prevention or delay
shall continue. The expression "Force Majeure" shall be deemed to include any
cause substantially affecting the performance by a party of this Agreement
arising from or attributable to acts, events, non-happenings, omissions or
accidents beyond the reasonable control of the party whose performance is so
affected.
32
<PAGE> 33
8.9 ASSIGNMENT. No party shall be entitled to assign its rights and
obligations hereunder without the prior written consent of the other parties;
provided, however, a party shall be entitled, without the prior written consent
of the other parties, to assign its rights and obligations hereunder to an
Affiliate, but such assignment to an Affiliate shall not relieve the assigning
party of its obligations hereunder. No permitted assignment hereunder shall be
deemed effective until the assignee shall have executed and delivered an
instrument in writing reasonably satisfactory in form and substance to the other
parties pursuant to which the assignee assumes all of the obligations of the
assigning party hereunder. Any purported assignment of this Agreement in
violation of this Section 8.9 shall be void. This Agreement shall be binding
upon the successors and permitted assigns of the parties and the name of a party
appearing herein shall be deemed to include the names of its successors and
assigns. Notwithstanding the foregoing provisions of this Section 8.9,
Purchaser's rights hereunder may be assigned as security to one or more
financial institutions providing financing to Purchaser and may be assigned
pursuant to the terms of the relevant security agreement, it being understood
that no such assignment shall release Purchaser from any of its obligations
hereunder (or be deemed to constitute an assumption by such an assignee of such
obligations) or increase or otherwise modify the obligations of Sellers
hereunder.
8.10 HEADINGS, INTERPRETATION. The headings used in this Agreement are for
convenience only and are not a part of this Agreement nor affect the
interpretation of any of its provisions.
8.11 ATTACHMENTS. All Exhibits and Schedules referenced herein are hereby
made a part of this Agreement.
8.12 INDEPENDENT PARTIES. This Agreement shall not be deemed to create any
partnership, joint venture, amalgamation or agency relationship between the
parties. Each party shall act hereunder as an independent contractor.
8.13 GOVERNING LAW. This Agreement shall be governed by and construed under
the laws of the State of Missouri, without giving effect to the choice of law
provisions thereof.
8.14 NO WAIVER. Neither the failure nor delay on the part of either party
to require the strict performance of any term, covenant or condition of this
Agreement or to exercise any right or remedy available on a breach thereof shall
constitute a waiver of any such breach or of any such term or condition. The
consent to, or the waiver of, any breach, or the failure to require on any
single occasion the performance or timely performance of any term, covenant, or
condition of this Agreement shall not be construed as authorizing any subsequent
or additional breach and shall not prevent a subsequent enforcement of such
term, covenant, or condition.
8.15 SEVERABILITY. In the event that any provision of this Agreement or the
application thereof to any party or circumstance shall be finally determined by
a court of proper jurisdiction to be invalid or unenforceable to any extent,
then (i) a suitable and equitable provision
33
<PAGE> 34
shall be substituted therefore in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid and unenforceable provision
and (ii) the remainder of this Agreement and the application of such provision
to the parties or circumstances other than those to which it is held invalid or
unenforceable shall not be affected thereby.
8.16 INTERPRETATION. The parties hereto acknowledge and agree that (i) each
party and its representatives has reviewed and negotiated the terms and
provisions of this Agreement and have contributed to its revision, (ii) the rule
of construction to the effect that any ambiguities are resolved against the
drafting party shall not be employed in the interpretation of this Agreement and
(iii) the terms and provisions of this Agreement shall be construed fairly as to
each party hereto and not in favor of or against either party regardless of
which party was generally responsible for the preparation of this Agreement.
8.17 COUNTERPARTS. This Agreement may be executed simultaneously in two or
more counterparts, each of which shall be deemed an original, but both of which
together shall constitute a single agreement.
8.18 THIRD PARTY BENEFICIARIES. This Agreement is not intended to confer
upon any non-party rights or remedies hereunder, except as may be received or
created as part of a valid assignment.
8.19 FURTHER ASSURANCES. Each party shall execute and deliver such
additional instruments and other documents and use all commercially reasonable
efforts to take or cause to be taken, all actions and to do, or cause to be
done, all things necessary under applicable law to consummate the transactions
contemplated hereby.
8.20 TERMS OF THIS AGREEMENT. The parties agree not to disclose any terms
or conditions of this Agreement or the Operative Agreements to any third party
without the prior written consent of the other party, except to advisors,
investors, lenders and others on a need-to-know basis under conditions which
reasonably ensure the confidentiality thereof, or to the extent required by Law;
provided, however, prior to any such required disclosure the non-disclosing
party shall be allowed to review the proposed disclosure, and the disclosing
party agrees to consider in good faith any proposed revisions thereof provided
to the disclosing party within two (2) business days of the non-disclosing
party's receipt of the proposed disclosure and the parties shall seek
confidential treatment for such disclosure as permitted by applicable Law.
34
<PAGE> 35
[Remainder of page intentionally left blank]
35
<PAGE> 36
IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to
be duly executed as of the date first above written.
SELLERS:
HOECHST MARION ROUSSEL, INC.
HOECHST MARION ROUSSEL
DEUTSCHLAND GMBH
PURCHASER:
KING PHARMACEUTICALS, INC.
36
<PAGE> 37
LIST OF OMITTED SCHEDULES AND EXHIBITS
(Registrant shall furnish supplementally a copy of any omitted
schedule to the Commission upon request).
Schedule 1.29 -- Excluded Know-How
Schedule 2.1(a)(i) -- International Trademarks
Schedule 2.1(a)(iii) -- International Authorizations
Schedule 2.1(a)(v) -- Manufacturing Equipment
Schedule 2.1(a)(vii)(A) -- International Assumed Contracts
Schedule 2.1(a)(vii)(B) -- Excluded International Assumed Contracts
Schedule 2.1(b)(i) -- U.S. Trademarks
Schedule 2.1(b)(ii) -- U.S. Authorizations
Schedule 2.1(b)(v)(A) -- U. S. Assumed Contracts
Schedule 2.1(b)(v)(B) -- Excluded U. S. Assumed Contracts
Schedule 2.2(a)(v) -- U.S. Product Research and Development
Schedule 2.3(b) -- Payment of Purchase Price
Schedule 4.1(d) -- Consents
Schedule 4.1(e) -- Liens
Schedule 4.1(f) -- Litigation
Schedule 4.1(g)(vii) -- Licenses to Trademarks
Schedule 4.1(i) -- Contracts
Schedule 4.1(k)(i) -- Regulatory Matters -- International Products
Schedule 4.1(k)(ii) -- Regulatory Matters -- U.S. Product
Schedule 4.1(k)(iii) -- Regulatory Matters -- Section 306(a) and 306(b)
Exhibit 1 -- U.S. Product Agreement
Exhibit 2 -- U.S. Product Manufacturing Agreement
Exhibit 3 -- International Products Manufacturing Agreement
Exhibit 4 -- Transition Services Agreement
Exhibit 5 -- Senior Subordinated Note(s)
Exhibit 6 -- General Assignment, Assumption and Irrevocable Bill of Sale
Exhibit 7 -- Assignment of Trademarks
Exhibit 8 -- Note Purchase Agreement(s)
Exhibit 9 -- Letter(s) of Credit
37
<PAGE> 1
EXHIBIT 99
NEWS RELEASE
KING PHARMACEUTICALS AND HOECHST MARION ROUSSEL SIGN
AN AGREEMENT FOR ONE OF THE LARGEST SINGLE PRODUCT
TRANSACTIONS IN EMERGING PHARMACEUTICAL SECTOR
Bristol, Tenn., Kansas City, Mo. December 17, 1998 - King Pharmaceuticals, Inc.
(NASDAQ:KING) and Hoechst Marion Roussel, the pharmaceutical company of Hoechst
AG, announced today the signing of a definitive agreement for King to acquire
three branded prescription pharmaceutical products from Hoechst Marion Roussel.
The products to be acquired include certain U.S. rights to Altace (R)
(ramipril), an Angiotensin Converting Enzyme ("ACE") inhibitor, and certain
worldwide rights to AVC(TM) (sulfanilamide), a vaginal anti-infective cream, and
to Silvadene(R) (silver sulfadiazine), a burn cream. Net sales for these
products, Altace(R) in the U.S., and Silvadene(R) and AVC(TM) globally, totaled
approximately $91.3 million during 1997 and $71.5 million during the first nine
months of 1998. Total consideration for the acquisition of the three branded
pharmaceutical products will equal $362.5 million. The parties expect to
complete the transaction by no later than Tuesday, December 22. King has
scheduled a related conference call at 10:00 a.m. EST Friday, December 18, 1998
at 1-800-275-3210.
King announced also today that it has obtained a related commitment from Credit
Suisse First Boston, First Union National Bank, and Bank of America to obtain a
senior secured credit facility in an aggregate principal amount of $500 million.
The proceeds of the credit facility will be used to finance the acquisition of
the three branded pharmaceutical products, to refinance certain existing
indebtedness of King, to fund working capital requirements, and for general
corporate purposes.
Altace(R), the largest product to be acquired by King, has U.S. patent
protection through 2008 and competes in the antihypertensive segment of the U.S.
cardiovascular pharmaceuticals market. The ACE inhibitor market has experienced
significant growth over the past five years driven primarily by the
effectiveness of ACE inhibitors in reducing patient blood pressure and wide
acceptance among prescribing physicians. Net sales for Altace(R) in the U.S.
totaled approximately $83.7 million during 1997.
John M. Gregory, Chairman and Chief Executive Officer of King, stated, "The
completion of this transaction will constitute the most significant acquisition
milestone to date for this Company. Moreover, we are extremely pleased that the
acquisition of certain U.S. rights to Altace(R) by King will represent one of
the largest product acquisitions ever completed in the U.S. by an emerging
growth pharmaceutical company." Mr. Gregory added, "The acquisition of Altace(R)
will dramatically expand King's presence in the approximately $5.5 billion U.S.
antihypertensive market and will exemplify once again the successful
implementation of our primary growth strategy to acquire additional branded
pharmaceutical products."
As part of the acquisition, King will enter into a six month Transition Services
Agreement whereby Hoechst Marion Roussel will provide King with sales and
marketing support and access to its medical staff and expertise for Altace(R).
Joseph R. Gregory, Vice Chairman of King and President and Chief Executive
Officer of Monarch Pharmaceuticals, Inc., a wholly-owned subsidiary of King,
commented, "The Transition Services Agreement with Hoechst Marion Roussel will
facilitate a smooth transition of Altace(R)
<PAGE> 2
to King, particularly in relation to the marketing of Altace(R) by our field
sales force of 161 representatives. The transition period correlates well with
the Company's plan to expand its field sales force to a total of 261
representatives before the third quarter of 1999, by hiring 50 representatives
during the first quarter and an additional 50 representatives during the second
quarter."
Gerald P. Belle, President of Hoechst Marion Roussel North America, shared this
perspective. "It is important to both companies that we handle the transition
period and the relationship beyond to our mutual benefit. This agreement
complements the fact that Hoechst Marion Roussel retains the rights to Altace(R)
(ramipril) outside of the U.S., as it remains an important growth product for us
throughout the world. Hoechst Marion Roussel is committed to continuing to
manufacture and market ramipril globally for years to come," he said.
Since December 1994, including the pending acquisition, King will have acquired
34 branded prescription pharmaceutical products. The company acquired from
Warner-Lambert Company 15 branded prescription pharmaceutical products, certain
manufacturing contracts for third parties, and a sterile manufacturing facility
operated by King's wholly-owned subsidiary. Parkedale Pharmaceuticals, Inc.
("Parkedale") during February 1998 and acquired Menest(R) (esterfied estrogens
tablets, USP), an oral estrogen replacement product, from SmithKline Beecham
Corporation during June 1998. Also during June 1998, King effected an initial
public offering of its common stock.
Jefferson J. Gregory, President of King and President and Chief Executive
Officer of Parkedale, observed, "The acquisition of the U.S. rights to Altace(R)
will culminate an impressive series of Company achievements during 1998,
including the Warner-Lambert acquisition in February and the subsequent FDA
approval of our supplemental Product License Application for Fluogen(R)
(Influenza Virus Vaccine, Trivalent, Types A and B) and of an additional
supplement for facility improvements that will enable the Company to
approximately double Influenza vaccine production capacity for next year. This
track record of accomplishments clearly demonstrates the extensive abilities and
enormous dedication of our Company's staff and management."
King, headquartered in Bristol, Tennessee, is a vertically integrated
pharmaceutical company that manufactures, markets and sells branded and generic
prescription pharmaceutical products. King seeks to capitalize on niche
opportunities in the pharmaceutical industry created by cost containment
initiatives and consolidation among large global pharmaceutical companies. The
Company's strategy is to acquire branded pharmaceutical products and increase
sales by focused promotion and marketing, as well as by product line extensions
and through product life cycle management.
Hoechst Marion Roussel is a leader in pharmaceutical-based health care,
dedicated to moving beyond medicine to health through the discovery and delivery
of prescription drugs and the provision of value-added patient support programs.
The global headquarters of Hoechst Marion Roussel are in Frankfurt, Germany, and
the North America headquarters are in Kansas City, Mo.
This release may contain forward-looking statements which reflect management's
current view of future events and operations. The forward-looking statements
involve certain significant risks and uncertainties, and actual results may
differ materially from the forward-looking statements. Some important factors
which may cause results to differ include: the Company's ability to consummate
the contemplated credit facility and product acquisition described above,
significant leverage and debt service requirements of the Company, dependence on
the Company's ability to continue to acquire branded products, dependence on
<PAGE> 3
sales of the Company's products, management of the Company's growth and
integration of its acquisitions. Other important factors that may cause actual
results to differ materially from the forward-looking statements are discussed
in "Risk Factors" and other sections of the Company's prospectus dated June 25,
1998, as part of the Company's Registration Statement on Form S-1, and discussed
in the Company's Form 10-Q for the quarter ended September 30, 1998, which are
one file with the Securities and Exchange Commission. The Company does not
undertake to publicly update or revise any of its forward-looking statements
even if experience or future changes show that the indicated results or events
will not be realized.
###
Contact:
Kyle P. Macione, Executive Vice-President, Investor Relations, King
Pharmaceuticals - 423-989-8077
Julie L. Gladman, Hoechst Marion Roussel - 816-966-4274
Traci M. Seaman, Hoechst Marion Roussel - 816-966-4104
<PAGE> 4
FOR IMMEDIATE RELEASE
KING PHARMACEUTICALS, INC. COMPLETES
ACQUISITION PREVIOUSLY ANNOUNCED
BRISTOL, TENNESSEE, December 22, 1998 -- King Pharmaceuticals, Inc.
(NASDAQ:KING) announced today that it has completed the acquisition of three
branded prescription pharmaceutical products from Hoechst Marion Roussel which
it announced last week. The products acquired include certain U.S. rights to
Altace(R) (ramipril), an Angiotensin Converting Enzyme ("ACE") inhibitor, and
certain worldwide rights to AVC (TM) (sulfanilamide), a vaginal anti-infective
cream, and to Silvadene(R) (silver sulfadiazine), a burn cream. The purchase
price for the three branded pharmaceutical products was $362.5 million. The
acquisition was financed, as planned, by a senior secured credit facility in an
aggregate principal amount of $500 million, which included funds to refinance
certain existing indebtedness of King, to fund working capital requirements and
to use for general corporate purposes.
King, headquartered in Bristol, Tennessee, is a vertically integrated
pharmaceutical company that manufactures, markets and sells branded and generic
prescription pharmaceutical products. King seeks to capitalize on niche
opportunities in the pharmaceutical industry created by cost containment
initiatives and consolidation among large global pharmaceutical companies. The
Company's strategy is to acquire branded pharmaceutical products and increase
sales by focused promotion and marketing, as well as by product line extensions
and through product life cycle management.
contact: Kyle P. Macione, Executive Vice President, Investor
Relations -- 423-989-8077
